FDA Rejects Novel Novartis Drug For Acute Heart Failure Forbes Novartis said it was “continuing to expand the data supporting the efficacy of RLX030 in acute heart failure with an extensive global clinical program, including the RELAX-AHF-2 trial which will enroll over 6,300 patients.” Move up http://i.forbesimg ... US regulator rejects Novartis heart failure drug FDA Says No to Serelaxin for Heart Failure Regulator Rejects Novartis Heart Failure Drug |
